GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (LTS:0RAG) » Definitions » 3-Year FCF Growth Rate

Abionyx Pharma (LTS:0RAG) 3-Year FCF Growth Rate : -57.50% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Abionyx Pharma 3-Year FCF Growth Rate?

Abionyx Pharma's Free Cash Flow per Share for the six months ended in Dec. 2023 was €-0.04.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -57.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 10.20% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 20.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 11 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Abionyx Pharma was 59.70% per year. The lowest was -57.50% per year. And the median was 9.50% per year.


Competitive Comparison of Abionyx Pharma's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Abionyx Pharma's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abionyx Pharma's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abionyx Pharma's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Abionyx Pharma's 3-Year FCF Growth Rate falls into.



Abionyx Pharma 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Abionyx Pharma  (LTS:0RAG) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Abionyx Pharma 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Abionyx Pharma's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Abionyx Pharma (LTS:0RAG) Business Description

Traded in Other Exchanges
Address
33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

Abionyx Pharma (LTS:0RAG) Headlines

No Headlines